Clovis Oncology, Inc. (CLVS) News

Clovis Oncology, Inc. (CLVS): $0.08

0.00 (-5.58%)

POWR Rating

Component Grades













Add CLVS to Watchlist
Sign Up

Industry: Biotech


of 385

in industry

Filter CLVS News Items

CLVS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CLVS News Highlights

  • CLVS's 30 day story count now stands at 11.
  • Over the past 17 days, the trend for CLVS's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
  • The most mentioned tickers in articles about CLVS are DRUG, AG and HA.

Latest CLVS News From Around the Web

Below are the latest news stories about CLOVIS ONCOLOGY INC that investors may wish to consider to help them evaluate CLVS as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!

William White on InvestorPlace | December 14, 2022

CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy

Clovis Oncology (CLVS) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection.

William White on InvestorPlace | December 12, 2022

Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis

Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.

Yahoo | December 12, 2022

Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.

Yahoo | December 12, 2022

Clovis Plans to Sell Cancer Drug to Novartis in Bankruptcy Deal

(Bloomberg) -- Clovis Oncology Inc. filed for bankruptcy and plans to sell its experimental cancer drug at an auction with Novartis Innovative Therapies making a binding, opening bid worth as much as $681 million.Most Read from BloombergChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeUS Says Scientists Make Breakthrough in Nuclear Fusion EnergyElon Musk Is Ruining Trump’s Presidential CampaignUS Stocks Start Fed Week Higher as CPI Data Loom: Markets WrapFed’s Message That Rates Will S

Yahoo | December 12, 2022

Cancer Focused Clovis Oncology Files For Bankruptcy

Clovis Oncology Inc (NASDAQ: CLVS) has voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process. The Debtors have filed various "first day" motions with the Bankruptcy Court requesting customary relief that will enable them to transition into Chapter 11 without material disruption to their ordinary course operations. Related: Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms. Clovis ha

Yahoo | December 12, 2022

Clovis Oncology stock slides 10% premarket after company files for bankruptcy

Clovis Oncology Inc. stock fell 10% in premarket trade Monday, after the biotech filed for Chapter 11 bankruptcy and said it would sell assets. The company has a commitment for up to $75 million in debtor-in-possession financing to provide the liquidity needed to restructure in bankruptcy and pay its vendors and customers. Before filing, the company entered a "stalking horse" agreement with Novartis AG to acquire the rights to its clinical candidate FAP-2286, for an upfront payment of $50 millio

Yahoo | December 12, 2022

UPDATE 1-Cancer drugmaker Clovis files for bankruptcy, hit by falling sales

Clovis has been struggling to sell its cancer drug Rubraca, the company's only approved drug, as sales were hit in recent years by intensifying competition from rival ovarian cancer treatments, and partly due to declining diagnoses during the pandemic lockdowns. The company has also lined up a debtor-in-possession (DIP) financing facility of up to $75 million to provide it with necessary liquidity, subject to court approval, Clovis said in a press release on Monday. Colorado-based Clovis said it has entered into a stalking horse agreement with Novartis Innovative Therapies AG to sell the license rights to its pipeline clinical candidate FAP-2286 for an upfront payment of $50 million and up to an additional $333.75 million after achieving some development and regulatory milestones.

Yahoo | December 12, 2022

U.S. drugmaker Clovis files for Chapter 11 bankruptcy

In a court filing at the U.S. Bankruptcy Court for the District of Delaware, Clovis estimated its assets were in range of $100 million to $500 million, while liabilities were between$500 million to $1 billion.

Yahoo | December 12, 2022

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

BOULDER, Colo., December 12, 2022--Clovis Oncology, Inc. (NASDAQ:CLVS) ("Clovis" or the Company"), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the "Debtors") have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware ("Bankruptcy Court") and w

Yahoo | December 12, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7934 seconds.